Does Amerigroup Cover Trulicity?

How Amerigroup Formulary Coverage Works for Trulicity

Amerigroup is a managed care organization operated by Elevance Health (formerly Anthem Inc.) that administers Medicaid, Medicare Advantage, and Children's Health Insurance Program (CHIP) plans across more than 20 states. Each state contract produces a separate preferred drug list (PDL), so Trulicity's exact tier placement varies by geography.

Medicaid Formulary Placement

On most Amerigroup Medicaid formularies, Trulicity sits at Tier 3 (preferred brand) within the antidiabetic drug class. Federal Medicaid rules under the Omnibus Budget Reconciliation Act of 1990 require state Medicaid programs to cover virtually all FDA-approved medications from manufacturers that participate in the Medicaid Drug Rebate Program [1]. Eli Lilly participates in this program, which means Amerigroup Medicaid plans cannot categorically exclude Trulicity. They can, however, impose utilization management controls such as prior authorization and step therapy.

Medicare Advantage Formulary Placement

For Amerigroup Medicare Advantage members, Trulicity typically appears on Part D formularies as a Tier 3 preferred brand or Tier 4 non-preferred brand, depending on the plan year and region. The Centers for Medicare & Medicaid Services (CMS) requires all Part D plans to cover at least two drugs in each pharmacological class, and GLP-1 receptor agonists qualify under the antidiabetic class [2]. Copays for Medicare Advantage members generally range from $35 to $95 for a 28-day supply before reaching the catastrophic coverage phase.

Checking Your Specific Plan

The fastest way to confirm coverage is to search the Amerigroup member portal for your state, enter "dulaglutide" in the formulary search tool, and review the tier, quantity limits, and prior authorization flags. Your plan's Evidence of Coverage (EOC) document will list the exact cost-sharing structure.

Prior Authorization Requirements for Trulicity on Amerigroup

Nearly every Amerigroup plan requires prior authorization (PA) before dispensing Trulicity. This is standard across Medicaid managed care for GLP-1 receptor agonists, which carry higher per-unit costs than older oral antidiabetics.

What the PA Criteria Typically Include

Amerigroup's PA criteria for Trulicity generally require documentation of all of the following: a confirmed diagnosis of type 2 diabetes mellitus, a recent hemoglobin A1c value (usually within the past 90 days), evidence that the patient has tried and failed metformin at a therapeutic dose for at least 90 days (or has a documented contraindication such as eGFR <30 mL/min/1.73 m² or gastrointestinal intolerance), and prescribing by or in consultation with an endocrinologist or primary care provider managing diabetes [3].

The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists as second-line therapy after metformin for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease (ASCVD) or high cardiovascular risk, stating: "For patients with type 2 diabetes and established ASCVD, a GLP-1 receptor agonist with proven cardiovascular benefit is recommended, independent of A1C" [3].

Turnaround Time and Appeals

Amerigroup must process standard PA requests within 72 hours for Medicaid members and 72 hours for Medicare Advantage non-urgent requests, per CMS and state regulatory requirements. Urgent requests require a 24-hour turnaround. If your PA is denied, you have the right to a first-level internal appeal and, if that fails, an external appeal through your state's Medicaid fair hearing process or Medicare's Independent Review Entity (IRE) [4].

Clinical Evidence Supporting Trulicity Coverage

Insurers base formulary decisions partly on clinical trial evidence. Trulicity has one of the more extensive evidence bases among GLP-1 receptor agonists, which supports its inclusion on most major formularies.

The REWIND Cardiovascular Outcomes Trial

The REWIND trial (N=9,901) randomized adults with type 2 diabetes to dulaglutide 1.5 mg weekly or placebo over a median follow-up of 5.4 years. Participants had a mean baseline A1c of 7.2% and a mean age of 66.2 years. Dulaglutide reduced the primary composite endpoint of major adverse cardiovascular events (MACE: cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) by 12% (HR 0.88, 95% CI 0.79 to 0.99, P=0.026) [5]. This trial was notable because roughly 69% of participants did not have established cardiovascular disease at enrollment, suggesting benefit in a primary prevention population.

Glycemic Efficacy Data

In the AWARD-1 trial (N=978), dulaglutide 1.5 mg reduced A1c by 1.51% from baseline at 26 weeks compared to 0.46% with placebo, a difference of 1.05 percentage points (P<0.001) [6]. The higher doses approved in 2020 (3 mg and 4.5 mg) produced additional A1c reductions of 1.71% and 1.87%, respectively, in the AWARD-11 trial (N=1,842) at 36 weeks [7].

Weight Effects

Dulaglutide produces moderate weight loss. Across AWARD program trials, mean weight reduction ranged from 1.5 kg to 4.6 kg depending on the dose and comparator. This is less than semaglutide (Ozempic), which produced 4.35 kg mean weight loss at the 1 mg dose in SUSTAIN-6 [8], but Trulicity remains a clinically meaningful option for patients who do not tolerate semaglutide or whose insurer preferences favor dulaglutide.

Dr. John Buse, Director of the Diabetes Center at the University of North Carolina School of Medicine and a principal investigator in GLP-1 trials, has noted: "The GLP-1 receptor agonist class has transformed how we think about type 2 diabetes treatment by addressing glycemia, weight, and cardiovascular risk simultaneously" [9].

Step Therapy: What to Try Before Trulicity Gets Approved

Amerigroup's step therapy protocol reflects national guideline recommendations and cost management priorities. Understanding the required sequence helps you prepare for the PA process.

First-Line: Metformin

The ADA Standards of Care and the American Association of Clinical Endocrinology (AACE) both position metformin as initial pharmacotherapy for most adults with type 2 diabetes [3]. Amerigroup typically requires a 90-day trial of metformin at doses of at least 1,500 mg daily before approving a GLP-1 receptor agonist. If metformin is contraindicated (renal impairment with eGFR <30, lactic acidosis history, severe GI intolerance), your prescriber can request a step therapy exception.

Preferred GLP-1 on Your Specific Plan

Some Amerigroup state plans designate a single preferred GLP-1 receptor agonist. In states where semaglutide (Ozempic) holds preferred status, Trulicity may require an additional step therapy failure or a non-formulary exception. In states where Trulicity is the preferred GLP-1, approval after metformin failure is typically straightforward. Check your state-specific PDL to determine which product holds preferred status.

Exceptions for Cardiovascular Indications

Patients with established ASCVD, heart failure with reduced ejection fraction, or chronic kidney disease may qualify for expedited GLP-1 approval without full step therapy, because guidelines specifically recommend GLP-1 receptor agonists with proven CV benefit in these populations regardless of A1c [3]. Your prescriber should cite the REWIND trial data and ADA recommendations in the PA request.

Expected Out-of-Pocket Costs With Amerigroup

Cost-sharing varies substantially between Amerigroup's Medicaid and Medicare Advantage product lines.

Medicaid Member Costs

Federal law caps Medicaid copayments. For most Medicaid beneficiaries, copays for preferred brand drugs like Trulicity range from $0 to $3.70 per prescription, depending on the state's cost-sharing schedule. Some states exempt certain populations (pregnant women, children, individuals below specific income thresholds) from copays entirely [10]. Trulicity's list price without insurance is approximately $1,067 per month for the 1.5 mg pen, but Medicaid members never pay list price.

Medicare Advantage Member Costs

Medicare Advantage members face higher cost-sharing. During the initial coverage phase, Tier 3 copays for Trulicity typically fall between $35 and $95 for a 30-day supply. After reaching the $2,000 annual out-of-pocket maximum established by the Inflation Reduction Act (effective 2025), Part D members pay $0 for the remainder of the plan year [11]. This cap significantly reduces annual exposure for patients taking high-cost medications like GLP-1 receptor agonists.

Manufacturer Savings Programs

Eli Lilly offers the Trulicity Savings Card for commercially insured patients, reducing copays to as low as $25 per month. This card does not apply to government-funded insurance programs including Medicaid, Medicare, and Tricare. Lilly's patient assistance program, Lilly Cares, may provide Trulicity at no cost to uninsured or underinsured patients who meet income eligibility criteria (generally at or below 400% of the federal poverty level) [12].

What to Do If Amerigroup Denies Trulicity Coverage

A denial does not mean the end of the road. Several pathways exist.

File a Formal Appeal

Request the denial letter, which must include the specific clinical reason for the denial. Work with your prescriber to submit a peer-to-peer review or a written appeal that addresses each denial criterion. Include lab values, medication history, and relevant guideline citations. The REWIND trial data [5] and ADA Standards of Care [3] are the most commonly cited evidence in successful GLP-1 appeals.

Request a Formulary Exception

If Trulicity is non-preferred but another GLP-1 is preferred, your prescriber can request a formulary exception by documenting clinical reasons why the preferred agent is inappropriate (prior adverse reaction, contraindication, therapeutic failure).

Consider Covered Alternatives

If appeals are unsuccessful, discuss alternative GLP-1 receptor agonists that may hold preferred status on your Amerigroup plan. Options include semaglutide (Ozempic), liraglutide (Victoza), or exenatide extended-release (Bydureon BCise). Each has demonstrated cardiovascular and glycemic benefits, though the magnitude of effect differs across agents [8].

Trulicity Dosing and Administration Basics

Understanding how Trulicity is prescribed helps set expectations during the coverage approval process.

Starting and Titration Doses

Prescribers typically start Trulicity at 0.75 mg once weekly for at least 4 weeks, then increase to 1.5 mg weekly. If additional glycemic control is needed after at least 4 weeks on 1.5 mg, the dose can increase to 3 mg, and then to the maximum of 4.5 mg weekly [13]. Each dose uses a single-use, prefilled autoinjector pen.

Injection Technique

Trulicity is injected subcutaneously in the abdomen, thigh, or upper arm. The pen's hidden needle and one-click mechanism make it one of the simpler GLP-1 devices to use. Rotate injection sites with each dose. No reconstitution or dose dialing is required.

Common Side Effects

The most frequently reported adverse effects in clinical trials were gastrointestinal: nausea (12.4% at 0.75 mg, 21.1% at 1.5 mg), diarrhea (8.9%), and vomiting (6.0%) [6]. These effects typically diminish within the first 4 to 8 weeks of treatment. Gradual dose titration reduces GI symptom severity.

How Amerigroup Compares to Other Medicaid MCOs for GLP-1 Coverage

Amerigroup's approach to Trulicity coverage mirrors the broader Medicaid managed care field. Most Medicaid MCOs cover at least one GLP-1 receptor agonist on their PDL and require similar PA and step therapy protocols.

Relative Positioning

A 2023 analysis of Medicaid formularies across 10 states found that 87% of Medicaid managed care plans covered at least one GLP-1 receptor agonist without quantity limits beyond PA requirements, though the specific preferred agent varied by state and by which manufacturer offered the most favorable supplemental rebate [14]. Amerigroup's coverage of Trulicity falls within this mainstream pattern.

State-by-State Variation

Coverage generosity varies. States with higher Medicaid reimbursement rates and more flexible PDL committees tend to cover multiple GLP-1 options at preferred tiers. States with tighter pharmacy budgets may restrict coverage to a single preferred GLP-1 agent and require non-preferred exceptions for all others. Contact Amerigroup's pharmacy services line for your state (listed on the back of your member ID card) to confirm your plan's current PDL status for dulaglutide.